Browse News
Filter News
Found 1,010 articles
-
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
11/28/2023
Praxis Precision Medicines, Inc. announced that it will deliver presentations on its epilepsy programs at the following upcoming meetings in Orlando, Florida.
-
Montefiore Einstein Comprehensive Cancer Center Awarded FDA Grant for Clinical Trial on Experimental AML/MDS Treatment
11/28/2023
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)—two related blood diseases that disproportionally strike older adults—are notoriously difficult to treat and associated with high relapse rates.
-
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
11/16/2023
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) today announced that the European Medical Agency (EMA) has awarded its Priority Medicines (PRIME) designation for elsunersen (PRAX-222) for the treatment of SCN2A Gain of Function (GoF) developmental and epileptic encephalopathy (DEE).
-
Red Biotechnology Market Size to Garner Around USD 618.64 Billion by 2032
11/16/2023
The global red biotechnology market size is predicted to garner around USD 618.64 billion by 2032 and is expanding at a CAGR of 5.41% from 2023 to 2032.
-
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
11/11/2023
Ionis Pharmaceuticals, Inc. announced the completion of enrollment and positive preliminary findings from Part 1 of the ongoing HALOS Phase 1/2a study of ION582 in Angelman syndrome.
-
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
11/9/2023
Ionis Pharmaceuticals, Inc. announced positive results from an ongoing Phase 2 open-label extension study evaluating the safety and efficacy of its investigational prophylactic medicine, donidalorsen, in patients with hereditary angioedema, a rare and life-threatening genetic disease.
-
Ionis to present at upcoming investor conferences - November 03, 2023
11/3/2023
Ionis Pharmaceuticals, Inc. announced that management will participate in fireside chats at the following investor conferences.
-
Ionis reports third quarter 2023 financial results
11/2/2023
Ionis Pharmaceuticals, Inc., reported financial results for the third quarter of 2023.
-
Nonalcoholic Steatohepatitis (NASH) Market to Observe Stunning Growth by 2032 Owing to a Robust Pipeline
11/1/2023
The NASH market is expected to evolve because of emerging therapies like MGL-3196, Semaglutide, Vonafexor, HPG1860, VK2809, BIO89-100, LPCN 1144, and others.
-
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
10/25/2023
Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in mild Alzheimer’s disease (AD).
-
Opinion: The Potential of Neurofilament Light Chain as a Biomarker in Parkinson’s Disease
10/23/2023
While sensitive and specific biomarkers for Alzheimer’s disease have recently taken a leap forward, the Parkinson’s space has lagged behind. Neurofilament Light Chain could change that. -
The deal with PTC Therapeutics increases Royalty Pharma’s stake to 13% of total royalties garnered by Evrysdi, the blockbuster drug for spinal muscular atrophy licensed and marketed by Roche.
-
Ionis to hold third quarter 2023 financial results webcast
10/19/2023
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Thursday, November 2nd at 11:30 a.m. Eastern Time to discuss its third quarter 2023 financial results.
-
Flamingo Therapeutics Announces Poster Presentation at ESMO Congress 2023
10/17/2023
Flamingo Therapeutics announced the presentation of a "Trials-in-Progress", or TiP, poster at the ESMO Congress 2023, taking place October 20-24, 2023, in Madrid, Spain.
-
Recent FDA approvals of novel drugs based on less-than-stellar clinical evidence point to a trend toward regulatory flexibility—particularly in indications with very high unmet need.
-
Here’s how some biopharmas have managed to gain funding despite a falloff in investment in the sector. Hint: Positive late-stage data is a key factor.
-
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
10/4/2023
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) is holding an investor and analyst event, Ionis Innovation Day: Discovering, Developing and Delivering Transformational Medicines, in New York City today.
-
After a groundbreaking year in the Alzheimer’s space, Parkinson’s disease researchers express renewed hope based on a greater biological understanding of neurodegeneration.
-
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
10/2/2023
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, provided an update on its clinical portfolio at the company’s R&D Day.
-
The companies, which have been partners for a decade on various research programs, are pooling their efforts in two early-stage programs for Alzheimer’s and Huntington’s diseases using RNA-targeting medicines.